The 2026 ASCO living guideline update for stage IV non-small cell lung cancer is not one story. It is two. One document addresses patients without driver alterations, where the major work is careful regimen selection across PD-L1 subgroups and histology. The other addresses patients with driver alterations, where the pace of change has been much faster and where the biggest updates center on biomarker testing, EGFR-directed intensification, and new later-line options. ASCO published both full updates in February 2026, and the official podcast discussions around the guideline make clear that this was meant to consolidate multiple interim changes into a more usable clinical framework.
What changed most depends on which patient you are treating. In the driver-negative setting, the frontline framework is broadly familiar, but ASCO now places more explicit weight on comprehensive molecular testing up front, on the durability of long-term immunotherapy data, and on the fact that some subgroups, especially PD-L1-negative squamous disease, do not have one clearly superior regimen. In the driver-positive setting, the headline shift is more obvious: the guideline now favors combination first-line therapy for classic EGFR-mutant disease more strongly than before, while also adding new recommendations after progression on osimertinib.
Read About Metastatic Lung Cancer on OncoDaily
The Most Important Change May Be Testing, Not Treatment
One of the clearest messages in both 2026 ASCO updates is that clinicians should stop thinking of broad molecular testing as optional background work. In the official ASCO discussion of the updated guideline, Sonam Puri said biomarker testing should ideally include a broad-based next-generation sequencing panel, not single-gene assays, together with immunohistochemistry for PD-L1, HER2, and MET. She also noted that using both tissue and blood-based testing can improve the chances of identifying actionable results quickly, and that RNA-based sequencing is especially useful for detecting gene fusions that may otherwise be missed. Outside a truly resource-limited setting, she said, single-gene PCR testing should not be routine anymore.
The companion driver-negative update reinforces the same point. CancerNetwork’s report on the ASCO guideline states that the panel issued a strong recommendation for testing with a validated tissue and/or blood-based broad multigene panel, plus validated IHC assays for PD-L1, HER2, and MET, for all patients with NSCLC. The panel also emphasized that PD-L1 IHC alone is not sufficient to inform treatment decisions.
That may sound like a technical detail, but it is really the backbone of the whole update. The lack of a driver alteration is now just as important to document carefully as the presence of one, because it determines whether a patient should start with targeted therapy or move down the increasingly complex immunotherapy-based pathway. Joshua Reuss made exactly that point in the ASCO podcast, noting that the absence of a mutation is what leads a patient down the so-called driver-negative pathway in the first place.
In Driver-Negative Stage IV NSCLC, the Biggest Story Is Nuance, Not Revolution
The 2026 update for patients without driver alterations is important, but not because it introduces an entirely new frontline standard. Reuss was direct about this: there was not a lot of new trial data that changed frontline treatment in a sweeping way. Instead, the update reflects more mature follow-up from landmark immunotherapy studies and the practical challenge of choosing among multiple approved regimens without head-to-head comparisons. He emphasized that the guideline now has to function across six distinct clinical subgroups, created by combining squamous versus nonsquamous histology with PD-L1 high, PD-L1 low, and PD-L1-negative/unknown categories.
For nonsquamous NSCLC with PD-L1 TPS 50% or higher, ASCO strongly recommends single-agent pembrolizumab, cemiplimab, or atezolizumab. Combination strategies remain available in selected circumstances, including pembrolizumab or cemiplimab with carboplatin and pemetrexed, atezolizumab with carboplatin and taxane-based chemotherapy with or without bevacizumab, nivolumab plus ipilimumab, nivolumab/ipilimumab plus two cycles of chemotherapy, and durvalumab plus tremelimumab with platinum-containing chemotherapy.
For nonsquamous disease with PD-L1 1% to 49%, ASCO gives strong support to pembrolizumab or cemiplimab plus carboplatin and pemetrexed, while several other combination regimens remain conditional options. For PD-L1-negative or unknown nonsquamous disease, there are no strong recommendations for a single regimen, but multiple combination strategies may still be offered.
The squamous section is similar in broad structure but more complicated in practice. For PD-L1 50% or higher, ASCO strongly recommends single-agent pembrolizumab, cemiplimab, or atezolizumab. For PD-L1 1% to 49%, the strongest recommendation is for pembrolizumab or cemiplimab plus carboplatin and paclitaxel, while other combinations remain conditional. In PD-L1-negative squamous disease, the guideline no longer tries to elevate one regimen above the rest. Reuss said this was one of the subtle but important shifts in the 2026 update: the committee felt that no one regimen really was worthy of standing above the others in that subgroup.
That may be the most honest part of the update. The guideline is not pretending that all unanswered questions have now been solved. In some subsets, especially squamous PD-L1-negative disease, the right message is not “here is the one best regimen.” The right message is “there are several reasonable options, and patient-specific decision-making matters.”
The Later-Line Driver-Negative Space Is Becoming More Biomarker-Aware
The second-line and later-line sections of the driver-negative guideline are also worth attention. For patients with good performance status who received prior immune checkpoint inhibitor therapy alone, ASCO strongly recommends platinum-doublet chemotherapy. For patients who previously received chemotherapy plus immunotherapy, the guideline strongly recommends docetaxel with or without ramucirumab.
But what stands out in 2026 is how even the so-called driver-negative pathway is becoming more biomarker-aware. Conditional recommendations now include telisotuzumab vedotin for patients with c-MET overexpressing NSCLC and trastuzumab deruxtecan for those with HER2 IHC 3+ NSCLC. That does not erase the distinction between driver-positive and driver-negative disease, but it does show how quickly the later-line landscape is becoming more segmented and more dependent on good testing.
In Driver-Positive Disease, Classic EGFR NSCLC Is Where the Biggest Frontline Shift Happened
The driver-altered guideline is where the more visible changes happened. Puri said that since the last full update in 2024, there had been seven new regulatory approvals and changes in first-line therapy for some driver alterations, which is why ASCO considered a full refresh necessary. The most important frontline change was in classic EGFR-mutant NSCLC, meaning tumors with the usual sensitizing alterations such as exon 19 deletion or L858R.
The updated guideline now recommends offering either osimertinib plus platinum-pemetrexed chemotherapy or amivantamab plus lazertinib in the first-line setting for these patients. ASCO based that recommendation on the updated survival data from FLAURA2 and MARIPOSA, both of which showed improvements in progression-free survival and overall survival compared with osimertinib alone.
That said, ASCO did not push osimertinib monotherapy off the map. Puri was clear that although combination therapy is now preferred, osimertinib alone remains a reasonable option, particularly for patients with poor performance status or those who do not want treatment intensification after an informed discussion about the extra toxicity, infusion burden, and treatment frequency associated with combination therapy. That is a very practical and very welcome part of the guideline.
After Osimertinib, the Guideline Has New Direction
The 2026 update also sharpened what to do after progression on osimertinib. ASCO now recommends amivantamab plus chemotherapy after progression on osimertinib for patients with classic EGFR-mutant disease, based on MARIPOSA-2, which improved median PFS versus chemotherapy alone, though with greater toxicity. Puri emphasized that patients should be counseled carefully about the side-effect profile, which may be moderate to severe.
For patients who are not candidates for amivantamab plus chemotherapy, the guideline adds another option: platinum-based chemotherapy with or without continuation of osimertinib. The rationale comes from the COMPEL trial, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutant advanced NSCLC, all without CNS progression on first-line osimertinib, to platinum-pemetrexed with either continued osimertinib or placebo. Although small, the trial showed a PFS benefit for continuing osimertinib with chemotherapy. ASCO presents this as a reasonable option for patients without CNS progression who prefer or require a less intensive strategy than amivantamab-based treatment.
The guideline goes one step further after both osimertinib and platinum-based chemotherapy. Puri stated that datopotamab deruxtecan can now be offered in that setting. That is one of the most practically important additions in the later-line EGFR pathway, because it broadens options for a group of patients who historically reached chemotherapy-heavy territory quickly once osimertinib failed.
Read About FLAURA2 Trial on OncoDaily
What This Update Means in Real Practice
The easiest way to misunderstand the 2026 ASCO NSCLC update is to ask, “What is the new standard?” as if there were one universal answer. There is not. In the driver-negative setting, the update is less about replacing one regimen with another and more about recognizing where the evidence is strong, where it is subset-dependent, and where it is simply not precise enough to force a single preferred choice. In the driver-positive setting, especially for EGFR-mutant disease, the update is more directive: frontline intensification is now more clearly favored, but it comes with higher toxicity, so patient selection matters.
The most durable takeaway may still be the simplest one: get the testing right before you start treatment. That is the throughline that connects both documents. Broad NGS, blood plus tissue when needed, RNA-enabled fusion detection, PD-L1 plus HER2 plus MET assessment, and less reliance on single-gene PCR are no longer optional refinements for specialists. They are part of standard decision-making in stage IV NSCLC.
Bottom Line
What actually changed in the 2026 ASCO living guideline for stage IV NSCLC?
The biggest conceptual change is that ASCO now places even greater emphasis on complete up-front molecular profiling for all patients. In driver-negative disease, the frontline framework is mostly familiar, but the update adds more nuance, more long-term immunotherapy follow-up, and more honesty about where no single regimen clearly stands above the rest. In driver-positive disease, especially classic EGFR-mutant NSCLC, the update more clearly supports frontline combination therapy, adds amivantamab plus chemotherapy after osimertinib, allows chemotherapy with or without continued osimertinib in selected patients, and introduces datopotamab deruxtecan after both osimertinib and platinum-based chemotherapy.
It is not a guideline built around one dramatic new sentence. It is a guideline built around a more modern treatment philosophy: test broadly, treat precisely, and be honest when the data are strong, when they are nuanced, and when they are still incomplete.